Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Selenocysteine (Sec) is the 21st proteinogenic amino acid, structurally similar to cysteine but with a selenium atom replacing sulfur. It is an essential component of selenoproteins, a unique class of enzymes crucial for maintaining redox homeostasis, antioxidant defense, and various metabolic and endocrine pathways in humans. Selenocysteine is incorporated into polypeptides at specific UGA stop codons through a unique recoding mechanism. Its highly reactive selenol group contributes to its potent antioxidant and redox-regulatory activities. Emerging research highlights its therapeutic potential, particularly in nanotherapeutic formulations, where it has demonstrated direct inhibition of oxidative stress and ferroptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Selenocysteine.